CVS Health is expanding its drug offerings to include Eli Lilly's Zepbound and Novo Nordisk's Wegovy, while also considering an investment in Roche.

The entities involved

• CVS Health →

  company

  • CVS Health and Aetna are facing regulatory scrutiny in Tennessee as the state considers restricting major health insurers.Mon 15:23
  • Chevron Corporation and CVS Health are dividend stocks currently watched by investors.Sat 20:35
• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
• Novo Nordisk →

  Danish pharmaceutical company

  • BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
  • CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Mon 00:08

Related events

• Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.Aug 28
• Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.Sep 14
• Eli Lilly and Novo Nordisk are pushing for claims-level patient data submission.Sep 3
• Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.Sun 22:22
• Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.Jun 8